The Center for Disease Control reports that 1.6 million Americans received a dose of one of the approved Covid-19 vaccinations yesterday after a very slow start last month.
The Trump Administration promised 20 million vaccinations by December 31, but three weeks into January only 19 million have been vaccinated even as more than 400,000 Americans have died. Now the numbers are improving.
And 1 million new shots were reported in the previous 24-hour period, according to changes in CDC data from Wednesday morning to Thursday morning. That was only the second time a one-day increase rose above 1 million. The number of administered doses reported this week also was 22% higher than last week.
Confusion and money had been a problem up till now, as well as not enough medical workers or locations to administer the shots. All of which should improve considerably now that we have a President who cares enough to get the program working the way it should have from the beginning.
Joe Biden has promised 100 million Americans vaccinated in his first 100 days.
The 19 million doses administered to people represent about 48% of the 39.8 million doses that have been distributed, according to the CDC.
About 5% of the U.S. population — roughly 16.2 million people — has received at least one dose of the vaccine, and 2.75 million people are fully vaccinated, according to CDC data updated Friday morning.
Also, hopefully coming to the rescue are several new vaccines. Johnson and Johnson’s vaccine is thought to be only a couple of weeks from approval by the FDA, according to Dr. Anthony Fauci. Not only will this mean a third source of the shots, but this vaccine only requires a single dose, no special refrigeration, and has a long shelf life.
The AstraZeneca vaccine is already being used in a few countries. It was authorized in the UK in December, and in Brazil in January, but the FDA will likely want to use US data for any emergency use authorization in the US, Moncef Slaoui, chief adviser to the Trump administration's Operation Warp Speed, said last Tuesday.
Novavax’s vaccine started its phase three trials in the US and Mexico in December. Results are scheduled to be known by the end of March.